Branded

AcelRx's Dsuvia is indicated for acute pain severe enough to require an opioid analgesic for adults in medically supervised healthcare setting

Mayne Pharma is planning to launch halobetasol foam, a potent corticosteroid for plaque psoriasis, in early 2019.

Jazz Pharmaceuticals' FDA approval of a new indication for Xyrem gives narcolepsy patients age seven years old and older a treatment for cataplexy, or excessive daytime sleepiness,

Xofluza is the first new antiviral flu treatment with a novel mechanism of action approved by the Food and Drug Administration in nearly 20 years.

Sun Pharma is introducing its Ilumya injectable, which has been approved by the Food and Drug Administration, for the treatment of moderate-to-severe plaque psoriasis in adults.

Spectrum Pharmaceuticals' Khapzory for injection is the first Food and Drug Administration approved levoleucovorin product that contains sodium.

Fresenius Kabi is offering the first FDA-approved prefilled delivery system for palonosetron hydrochloride injection for cancer patients.

The FDA's approval of Regeneron and Sanofi's Dupixent provides patients with moderate-to-severe asthma, age 12 years old and older, with a new treatment option.